IN2012DN01573A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01573A IN2012DN01573A IN1573DEN2012A IN2012DN01573A IN 2012DN01573 A IN2012DN01573 A IN 2012DN01573A IN 1573DEN2012 A IN1573DEN2012 A IN 1573DEN2012A IN 2012DN01573 A IN2012DN01573 A IN 2012DN01573A
- Authority
- IN
- India
- Prior art keywords
- disorders
- disorder
- diseases
- absorption
- methods
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 abstract 3
- 229960001570 ademetionine Drugs 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 208000012659 Joint disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 241000149788 Pseudophryne major Species 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000024732 dysthymic disease Diseases 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention relates to compositions and methods to enhance the absorption of S-adenosylmethionine (SAMe) and to methods of treatingvarious disorders or diseases using non-parenteral SAMe formulations with enhanced-absorption and improved bioavailability. The enhanced bioavailability formulations may be used to treat a variety of diseases or disorders, such as for example, psychiatric disorders including, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, depressive disorders (e.g. major clinical depression) and dysthymia; as well as treating liver disorders, cancer, autoimmune disorders, inflammatory disorders, joint disorders, gastrointestinal disorders and cardiovascular disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22919409P | 2009-07-28 | 2009-07-28 | |
PCT/IB2010/001877 WO2011012989A1 (en) | 2009-07-28 | 2010-07-29 | S-adenosylmethionine formulations with enhanced bioavailability |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN01573A true IN2012DN01573A (en) | 2015-06-05 |
Family
ID=43527258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1573DEN2012 IN2012DN01573A (en) | 2009-07-28 | 2010-07-29 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20110027342A1 (en) |
EP (1) | EP2512490B1 (en) |
JP (1) | JP2013505896A (en) |
KR (1) | KR20120090038A (en) |
CN (1) | CN102695514A (en) |
AU (1) | AU2010277301B2 (en) |
CA (1) | CA2769582A1 (en) |
HK (1) | HK1170155A1 (en) |
IN (1) | IN2012DN01573A (en) |
WO (1) | WO2011012989A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090088404A1 (en) * | 2007-01-31 | 2009-04-02 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
US20110027342A1 (en) * | 2009-07-28 | 2011-02-03 | Msi Methylation Sciences, Inc. | S-adenosylmethionine formulations with enhanced bioavailability |
WO2012012902A1 (en) * | 2010-07-28 | 2012-02-02 | Msi Methylation Sciences Inc. | S-adenosylmethionine formulations with enhanced bioavailability |
US8329208B2 (en) * | 2009-07-28 | 2012-12-11 | Methylation Sciences International Srl | Pharmacokinetics of S-adenosylmethionine formulations |
WO2014059522A1 (en) * | 2012-10-17 | 2014-04-24 | Methylation Sciences International Srl | Compositions comprising s-adenosylmethionine and a gallic acid ester |
CA2906955A1 (en) * | 2013-03-15 | 2014-09-18 | Hunan Skyworld Biotechnologies Co. Ltd. | Immunoassay of s-adenosylmethionine using analogs thereof and personalized therapeutics |
US20150112089A1 (en) * | 2013-10-22 | 2015-04-23 | Metselex, Inc. | Deuterated bile acids |
ITMI20131906A1 (en) | 2013-11-18 | 2015-05-19 | Gnosis Spa | ORAL SOLID COMPOSITIONS WITH SLOW RELEASE |
CN106714810A (en) * | 2014-04-14 | 2017-05-24 | 甲基化物科学国际有限公司 | Novel ademetionine formulations |
CA3042699A1 (en) | 2016-11-03 | 2018-08-09 | Alexander Vuckovic, M.D., Llc | Compositions and methods for treating depression |
WO2019023245A1 (en) * | 2017-07-25 | 2019-01-31 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
WO2021106004A1 (en) * | 2019-11-25 | 2021-06-03 | Kusum Healthcare Pvt. Ltd. | Pharmaceutical composition of s-adenosylmethionine |
CN114306266A (en) * | 2022-01-06 | 2022-04-12 | 济南同路医药科技发展有限公司 | Enteric composition of adenosine methionine butanedisulfonate and preparation method thereof |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE37913B1 (en) * | 1972-08-02 | 1977-11-09 | Bioresearch Sas | Salt of s-adenosyl-l-methionine |
IE39517B1 (en) * | 1973-06-27 | 1978-10-25 | Bioresearch Sas | Double salts of s-adenosyl-l-methhionine |
AR221676A1 (en) * | 1974-07-12 | 1981-03-13 | Bioresearch Sas | PROCEDURE FOR THE PREPARATION OF SULPHONIC AND / OR SULFURIC STABLE SALTS OF S-ADENOSIL-L-METIONINE, PARTICULARLY USEFUL AS SPECIFIC METHYL DONORS FOR THE CH3, ELAMIBLI-TRANSFERRING BIOCHEMICAL AND LATIN-GLOBAL ELEMENTS PROTILICO AND GLUCIDICO |
US5264446A (en) * | 1980-09-09 | 1993-11-23 | Bayer Aktiengesellschaft | Solid medicament formulations containing nifedipine, and processes for their preparation |
US4525345A (en) * | 1981-12-24 | 1985-06-25 | Verex Laboratories, Inc. | Constant order release, solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions |
US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4556678A (en) * | 1982-06-24 | 1985-12-03 | Key Pharmaceuticals, Inc. | Sustained release propranolol tablet |
DE3435325A1 (en) * | 1983-04-09 | 1986-04-17 | Nikken Chemicals Co., Ltd., Tokio/Tokyo | LONG-TERM THEOPHYLLIN TABLET AND METHOD FOR THE PRODUCTION THEREOF |
US4680323A (en) * | 1983-12-01 | 1987-07-14 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration |
US4537772A (en) * | 1984-05-02 | 1985-08-27 | Merck & Co., Inc. | Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines |
IT1173992B (en) * | 1984-05-16 | 1987-06-24 | Bioresearch Spa | STABLE SALTS OF SULPHO-ADENOSYL-METHIONINE (SAME) PARTICULARLY SUITABLE FOR ORAL PHARMACEUTICAL USE |
US4601894A (en) * | 1985-03-29 | 1986-07-22 | Schering Corporation | Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate |
US4695591A (en) * | 1985-03-29 | 1987-09-22 | Schering Corporation | Controlled release dosage forms comprising hydroxypropylmethylcellulose |
US4687757A (en) * | 1986-03-24 | 1987-08-18 | Phillips Petroleum Company | Hydrofining catalyst composition and process for its preparation |
US4756911A (en) * | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US5200193A (en) * | 1987-04-22 | 1993-04-06 | Mcneilab, Inc. | Pharmaceutical sustained release matrix and process |
US5073380A (en) * | 1987-07-27 | 1991-12-17 | Mcneil-Ppc, Inc. | Oral sustained release pharmaceutical formulation and process |
US4968509A (en) * | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
FR2623396B1 (en) * | 1987-11-25 | 1990-03-30 | Sanofi Sa | USE OF ADEMETIONINE AGAINST AGING SKIN |
US5169642A (en) * | 1988-06-24 | 1992-12-08 | Abbott Laboratories | Sustained-release drug dosage units |
IT1229477B (en) * | 1989-03-13 | 1991-09-03 | Bioresearch Spa | USE OF 5 'DEOXY - 5' METHYLTHIOADENOSINE, S ADENOSYLMETHIONINE AND THEIR SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS TO REDUCE SEBORRHEA AND RELATED PHARMACEUTICAL COMPOSITIONS |
US5137712A (en) * | 1990-08-31 | 1992-08-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent supersensitivity, tolerance and extrapyramidal side effects induced by neuroleptic treatment |
IT1243859B (en) * | 1990-10-23 | 1994-06-28 | Bioresearch Spa | PHARMACEUTICAL COMPOSITIONS INCLUDING ASSOCIATIONS BETWEEN S-ADENOSYL-L-METHIONINE SALTS AND 5-METHYL (OR 5-FORMYL) -TETHYDROPHOLIC ACID FOR THE TREATMENT OF NEUROLOGICAL COMPLICATIONS IN AIDS SICKS. |
US5543154A (en) * | 1991-12-27 | 1996-08-06 | Merck & Co., Inc. | Controlled release nifedipine delivery device |
IL104192A (en) * | 1992-02-17 | 1998-01-04 | Siegfried Ag Pharma | Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient |
CA2217696A1 (en) * | 1995-04-25 | 1996-10-31 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
DE19631085A1 (en) * | 1996-08-01 | 1998-02-05 | Basf Ag | Use of (meth) acrylic acid-maleic acid copolymers to improve the permeability of the mucosa |
DE19631084A1 (en) * | 1996-08-01 | 1998-02-05 | Basf Ag | Use of (meth) acrylic acid copolymers to increase the permeability of the mucosa |
US5922341A (en) * | 1997-10-28 | 1999-07-13 | Vivus, Incorporated | Local administration of pharmacologically active agents to treat premature ejaculation |
US6365185B1 (en) * | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
US7906153B2 (en) * | 1998-04-08 | 2011-03-15 | Theta Biomedical Consulting & Development Co., Inc. | Anti-inflammatory compositions for treating multiple sclerosis |
US7060479B2 (en) * | 1999-12-08 | 2006-06-13 | Serono Genetics Institute, S.A. | Full-length human cDNAs encoding potentially secreted proteins |
DE19839443A1 (en) * | 1998-08-29 | 2000-03-02 | Miklos Ghyczy | Pharmaceutical and dietetic product contains quaternary ammonium compound and/or S-adenosyl-methionine, useful for treatment of oxygen deficiency and energy metabolism disorders and NSAID side effects |
BR9913745B1 (en) * | 1998-09-15 | 2011-05-31 | pyridine ketones, herbicidal composition and plant growth inhibitor, its use, method for controlling unwanted plant growth, as well as method for inhibiting plant growth. | |
EP1027885B1 (en) * | 1999-02-09 | 2008-07-09 | Pfizer Products Inc. | Basic drug compositions with enhanced bioavailability |
BR0110316A (en) * | 2000-04-07 | 2005-01-18 | Regents For The University Of | Unique Zwitterionic Phospholipid and Bisphosphonate Compositions and Use of the Compositions as Bisphosphate Delivery Systems with Reduced Gly Toxicity |
US6944766B2 (en) | 2000-05-02 | 2005-09-13 | Canon Kabushiki Kaisha | Information processing apparatus |
US6759395B2 (en) * | 2000-12-18 | 2004-07-06 | Orchid Chemicals & Pharmaceuticals, Ltd. | Soft-gelatin capsule comprising S-adenosylmethionine and a method for producing the same |
GB0111579D0 (en) * | 2001-05-11 | 2001-07-04 | Holford & Associates Ltd | Oral supplement |
ATE425744T1 (en) * | 2002-04-29 | 2009-04-15 | Supernus Pharmaceuticals Inc | PHARMACEUTICAL FORMULATIONS WITH IMPROVED BIOAVAILABILITY |
US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
CN102697704A (en) * | 2003-09-26 | 2012-10-03 | 阿尔扎公司 | Controlled release formulations of opioid and nonopioid analgesics |
CA2543185A1 (en) * | 2003-10-31 | 2005-05-12 | Alza Corporation | Compositions and dosage forms for ehnanced absorption of iron |
JP2007517039A (en) * | 2003-12-24 | 2007-06-28 | アドバンシス ファーマスーティカル コーポレイション | Enhanced absorption of modified release formulations |
US20050191349A1 (en) * | 2003-12-31 | 2005-09-01 | Garth Boehm | Galantamine formulations |
US7429569B2 (en) * | 2004-01-29 | 2008-09-30 | Fast Balance, Inc. | Compositions and methods for the regulation of homocysteine levels within the body |
US20050181047A1 (en) * | 2004-02-18 | 2005-08-18 | Jaime Romero | Compositions and methods for timed release of water-soluble nutritional supplements |
US20060127506A1 (en) * | 2004-12-10 | 2006-06-15 | Hebert Rolland F | Compositions of S-adenosyl-L-methionine |
US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
CN101534808A (en) * | 2005-06-27 | 2009-09-16 | 拜维尔实验室国际有限公司 | Modified-release formulations of a bupropion salt |
NZ570427A (en) * | 2006-02-09 | 2011-10-28 | Alba Therapeutics Corp | Formulations for a tight junction effector |
EP1993356A2 (en) * | 2006-02-09 | 2008-11-26 | Alba Therapeutics Corp. | Oral delivery of therapeutic agents using tight junction agonists |
ITMI20060629A1 (en) * | 2006-03-31 | 2007-10-01 | Daniele Giovannone | ORAL SOLID COMPOSITIONS BASED ON S-ADENOSYLMETIONINE AND PROCESS FOR THEIR ACHIEVEMENT |
CA2677053C (en) * | 2007-01-31 | 2016-03-15 | Methylation Sciences International Srl | Extended release pharmaceutical formulations of s-adenosylmethionine |
US20090088404A1 (en) * | 2007-01-31 | 2009-04-02 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
US20090197824A1 (en) * | 2008-01-31 | 2009-08-06 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
US20080279931A1 (en) * | 2007-05-09 | 2008-11-13 | Northern Holdings Inc. | Composition for treatment of pain |
ITMI20081405A1 (en) * | 2008-07-29 | 2010-01-30 | Velleja Res Srl | INSTANT ORAL FORMULATIONS, GELIFICANTS AT AMBIENT TEMPERATURE, USEFUL TO CONTRAST THE ORGANIC DEPERMENT AND THE DEPRESSIVE SYNDROME RELATED TO CACHESSIA, ANORESSIA, METABOLIC DISEASE, ENDOCRINE DISEASE AND DYSFAGY |
WO2010027014A1 (en) * | 2008-09-04 | 2010-03-11 | 株式会社カネカ | Method for improving absorption of s-adenosyl-l-methionine, and composition having improved s-adenosyl-l-methionine absorption |
EP2193787A1 (en) * | 2008-12-02 | 2010-06-09 | Giorgio Stramentinoli | Formulations for systemic buccal delivery comprising s-adenosylmethionine, their preparation and use |
US8329208B2 (en) * | 2009-07-28 | 2012-12-11 | Methylation Sciences International Srl | Pharmacokinetics of S-adenosylmethionine formulations |
US20110027342A1 (en) * | 2009-07-28 | 2011-02-03 | Msi Methylation Sciences, Inc. | S-adenosylmethionine formulations with enhanced bioavailability |
-
2010
- 2010-07-28 US US12/845,555 patent/US20110027342A1/en not_active Abandoned
- 2010-07-29 JP JP2012522272A patent/JP2013505896A/en active Pending
- 2010-07-29 CN CN201080044205XA patent/CN102695514A/en active Pending
- 2010-07-29 EP EP10803973.6A patent/EP2512490B1/en not_active Not-in-force
- 2010-07-29 KR KR1020127005274A patent/KR20120090038A/en not_active Application Discontinuation
- 2010-07-29 AU AU2010277301A patent/AU2010277301B2/en not_active Ceased
- 2010-07-29 IN IN1573DEN2012 patent/IN2012DN01573A/en unknown
- 2010-07-29 WO PCT/IB2010/001877 patent/WO2011012989A1/en active Application Filing
- 2010-07-29 CA CA2769582A patent/CA2769582A1/en not_active Abandoned
-
2011
- 2011-07-27 US US13/811,772 patent/US20130142847A1/en not_active Abandoned
-
2012
- 2012-10-29 HK HK12110807.8A patent/HK1170155A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2011012989A1 (en) | 2011-02-03 |
CN102695514A (en) | 2012-09-26 |
HK1170155A1 (en) | 2013-02-22 |
JP2013505896A (en) | 2013-02-21 |
EP2512490A1 (en) | 2012-10-24 |
CA2769582A1 (en) | 2011-02-03 |
KR20120090038A (en) | 2012-08-16 |
EP2512490A4 (en) | 2012-12-26 |
AU2010277301A1 (en) | 2012-03-15 |
US20130142847A1 (en) | 2013-06-06 |
AU2010277301B2 (en) | 2014-01-23 |
EP2512490B1 (en) | 2016-01-27 |
US20110027342A1 (en) | 2011-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN01573A (en) | ||
WO2010009449A3 (en) | Extended release pharmaceutical formulations of s-adenosylmethionine | |
WO2010008619A3 (en) | Extended release pharmaceutical formulations of s-adenosylmethionine | |
MX2009013990A (en) | Methods of treating serotonin-mediated diseases and disorders. | |
EA201270575A1 (en) | CONNECTIONS | |
EA201490132A1 (en) | ANTI-VIRUS COMPOUNDS | |
EA201190217A1 (en) | SUBSTITUTED 2-ACETAMIDO-5-ARIL-1,2,4-TRIAZOLONES AND THEIR APPLICATION | |
WO2012075492A3 (en) | Carbocycle-substituted purine and 7-deazapurine compounds | |
UA101493C2 (en) | Azetidine and cyclobutane derivatives as jak inhibitors | |
MA32771B1 (en) | FGF21 MUTANTS AND USES THEREOF | |
MX356584B (en) | Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease. | |
EA201001639A1 (en) | COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND APPLICATION | |
WO2007022225A3 (en) | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | |
EA200901166A1 (en) | CONNECTIONS AND COMPOSITIONS AS GPR 119 ACTIVITY MODULATORS | |
EA201190259A1 (en) | ANTI-VIRUS COMPOUNDS | |
EA201100299A1 (en) | ORGANIC COMPOUNDS | |
WO2008085794A3 (en) | Methods and compositions related to clot binding compounds | |
NO345046B1 (en) | Oral dosage form | |
UA92497C2 (en) | Erythropoietin receptor peptide formulations and uses | |
EA201171435A1 (en) | SOLID PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR PRODUCTION | |
UA92636C2 (en) | Tetrahydro-pyrimidoazepines as modulators of trpv1 | |
MY145349A (en) | Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor | |
EA201101686A1 (en) | NEW COMPOSITIONS FOR THE TREATMENT OF CMT AND RELATED DISORDERS | |
SMT201600332B (en) | COMPOSITIONS AND METHODS FOR THE INCREASE OF THE TELOMERASICA ACTIVITY | |
BR112013001753A2 (en) | a method for preparing a plasma erected alpha-inhibitor (aiip) composition, aqueous iaip solution, and a method for treating a disease or disorder associated with iaip dysfunction and associated with increased plasma serine protease activity. |